Early Clinical Development
Optimize your early clinical development program
To shorten the development timeline of complex molecules, many biopharma companies are moving toward hybrid early clinical development (ECD) study models, which require both healthy volunteers and patient populations. Finding the right patients, target, dose/exposure, response and commercial strategy are essential criteria for successful clinical development. Leverage a fit-for-purpose model to tackle these challenges and deliver a better proof-of-concept during your Phase I trial.
IQVIA is the recognized industry leader in Phase I trials, fueled by a history of executing early clinical development trials around the world. With global resources to enhance your Phase I study’s speed, quality, and safety, whether First-in-Human, First-in-Patient, or Healthy Volunteer studies, we work seamlessly with your unique protocol and systems – from the very start.
Proactive. Scalable. Fit-to-purpose. With deep, global experience and an extensive global network of sites. Our models for success can take you from first steps to a quality outcome.
Learn more about our Early Clinical Development capabilities.
By: Stephen Evans